Mesenchymal stromal cell therapy in ischemic heart disease.

Item

http://www.wikidata.org/entity/Q38886932

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Mesenchymal stromal cell therapy in ischemic heart disease.

@en

type

Item

label

Mesenchymal stromal cell therapy in ischemic heart disease.

@en

prefLabel

Mesenchymal stromal cell therapy in ischemic heart disease.

@en

P1476

Mesenchymal stromal cell therapy in ischemic heart disease.

@en

P2093

Abbas Ali Qayyum

http://www.w3.org/2001/XMLSchema#string

Anders Bruun Mathiasen

http://www.w3.org/2001/XMLSchema#string

Jens Kastrup

http://www.w3.org/2001/XMLSchema#string

Mandana Haack-Sørensen

http://www.w3.org/2001/XMLSchema#string

Naja Dam Mygind

http://www.w3.org/2001/XMLSchema#string

P2860

Adipose-derived mesenchymal stromal cells for chronic myocardial ischemia (MyStromalCell Trial): study design

Paracrine mechanisms in adult stem cell signaling and therapy

The immunomodulatory capacity of mesenchymal stem cells.

Meta-Analysis of Cell-based CaRdiac stUdiEs (ACCRUE) in patients with acute myocardial infarction based on individual patient data.

Human relevance of pre-clinical studies in stem cell therapy: systematic review and meta-analysis of large animal models of ischaemic heart disease.

Adipose tissue-derived multipotent stromal cells have a higher immunomodulatory capacity than their bone marrow-derived counterparts.

Percutaneous, transendocardial injection of bone marrow-derived mononuclear cells in heart failure patients following acute ST-elevation myocardial infarction: ALSTER-Stem Cell trial.

Bone Marrow Stem Cell Treatment for Ischemic Heart Disease in Patients with No Option of Revascularization: A Systematic Review and Meta-Analysis.

Comparison of allogeneic vs autologous bone marrow–derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial

A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction.

P304

293-299

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14017431.2016.1210213

http://www.w3.org/2001/XMLSchema#string

P433

5-6

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Annette Ekblond

P577

2016-07-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27380735

http://www.w3.org/2001/XMLSchema#string